BioPharm Systems Named to the 2010 Inc. 500:5000 List of Fastest-Growing Companies in the U.S.
BioPharm Systems announced that it has been named to Inc. magazine's list of the fastest-growing private companies in the United States for 2010. The Inc. 500|5000 ranks companies by overall revenue growth over a three-year period. BioPharm Systems was recognized for its 60 percent three-year growth rate.
"We are honored to be named among the many other prestigious companies in America," said Alex Sefanov, president and CEO of BioPharm Systems. "BioPharm has been growing at a consistent rate for many years. Our team continues to develop and provide new solutions in order to meet our clients' needs. This past year we launched a Siebel Clinical Trial Management System (CTMS) accelerator called ASCEND, and it has been generating a lot of interest due to its robust features, cost-effectiveness, and fast implementation process. We also have developed several other solutions, including Accel-Transfer, which is a tool that extracts, transforms, and loads data from one safety application into another.
BioPharm Systems, an Oracle Gold Partner specializing in Oracle Health Sciences' suite of clinical and safety applications, opened an office in the United Kingdom earlier this year.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
